Why Kura Oncology shares tumbled after securing a $1.2bn cancer-drug partnership
Kura Oncology, Inc., a clinical-stage biopharmaceutical innovator, and Japan-based pharmaceutical leader Kyowa Kirin Co., Ltd., have entered into a strategic partnership that could redefine treatment for acute myeloid leukemia (AML). The collaboration focuses on ziftomenib, an investigational oral menin inhibitor that has garnered attention as a potential breakthrough therapy for genetically defined AML patients. This […]
